newsfilter
← Latest News
Business Wire·

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS Merck